Lilly’s Mounjaro does not need separate indication for sleep apnea, EMA panel determines

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has determined that Eli Lilly’s (NYSE:LLY) weight-loss drug Mounjaro (tirzepatide) does not need a separate indication for the treatment of obstructive sleep apnea (OSA).

The Committee for Medicinal Products for Human Use (CHMP) considered that the use of Mounjaro is already covered by the approved indication for weight management and that a separate indication for the treatment of moderate to severe OSA in adults with obesity is not needed.

Mounjaro is used together with diet and physical activity to treat adults with type 2 diabetes which is not satisfactorily controlled. It is also used together with diet and physical activity to help people with obesity or who are overweight and who have weight-related health problems lose weight and keep their weight under control.

Lilly (LLY) is also seeking approval for the drug in sleep apnea patients in the U.S.

More on Eli Lilly

• Lilly’s Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
• Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
• Eli Lilly: Steep Pullback, Still Compelling Here
• Lilly reports positive Phase 3 breast cancer data for imlunestrant
• Lilly to sell Zepbound through telehealth platform Ro